ClinicalTrials.govpublic full text
Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCC
esophageal cancer, liposomal irinotecan, second-line therapy, esophageal squamous cell carcinoma, interventional, phase3
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 914641
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.